Assertio Stock Story

ASRT
 Stock
  

USD 2.85  0.04  1.38%   

As many rational traders are trying to avoid healthcare space, it makes sense to review Assertio Holdings a little further and understand how it stands against FSD Pharma and other similar entities. We are going to break down some of the competitive aspects of both Assertio and FSD Pharma.
Published over three months ago
View all stories for Assertio Holdings | View All Stories

Assertio Holdings Current Investor Sentiment

Investor biases related to Assertio Holdings' public news can be used to forecast risks associated with investment in Assertio. The trend in average sentiment can be used to explain how an investor holding Assertio can time the market purely based on public headlines and social activities around Assertio Holdings. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Assertio Holdings' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Assertio Holdings' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Assertio Holdings' news discussions. The higher the estimate score, the more favorable is the investor's outlook on Assertio Holdings.
Are FSD Pharma (NASDAQ:HUGE) private investors switching to Assertio (NASDAQ:ASRT)?
By analyzing existing basic indicators between Assertio Holdings and FSD Pharma, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in FSD Pharma with a short position in Assertio Holdings. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Assertio Holdings has an asset utilization ratio of 2033.73 percent. This implies that the company is making $20.34 for each dollar of assets. An increasing asset utilization means that Assertio Holdings is more efficient with each dollar of assets it utilizes for everyday operations.

How important is Assertio Holdings's Liquidity

Assertio Holdings financial leverage refers to using borrowed capital as a funding source to finance Assertio Holdings ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Assertio Holdings financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Assertio Holdings's total debt and its cash.

How does Assertio utilize its cash?

To perform a cash flow analysis of Assertio Holdings, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Assertio Holdings is receiving and how much cash it distributes out in a given period. The Assertio Holdings cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Assertio Holdings Net Cash Flow from Operations is comparatively stable at the moment as compared to the past year. Assertio Holdings reported Net Cash Flow from Operations of 5.52 Million in 2021

A Deeper Perspective

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Now, let's check Assertio Holdings revenue. Based on the latest financial disclosure, Assertio Holdings reported 109.71 M of revenue. This is 98.56% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is 98.84% higher than that of Assertio Holdings. As for FSD Pharma we see revenue of 11.91 M, which is much higher than that of the Drug Manufacturers—Specialty & Generic

ASRT
109.7 M
ASRT109.71 Million90.21
Sector0.00.0
HUGE11.91 Million9.79

Another 3 percent gain for Assertio Holdings

The total risk alpha is down to 1.58 as of today.
As of the 9th of March, Assertio Holdings shows the Mean Deviation of 5.7, downside deviation of 4.75, and Risk Adjusted Performance of 0.1356. Assertio Holdings technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Assertio Holdings, which can be compared to its rivals. Please confirm Assertio Holdings standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Assertio Holdings is priced correctly, providing market reflects its regular price of 2.41 per share. Please also double-check Assertio Holdings total risk alpha, which is currently at 1.58 to validate the company can sustain itself at a future point.

Our Conclusion on Assertio Holdings

Whereas many other companies within the drug manufacturers—specialty & generic industry are still a little expensive, even after the recent corrections, Assertio Holdings may offer a potential longer-term growth to private investors. To conclude, as of the 9th of March 2022, our analysis shows that Assertio Holdings almost mirrors the market. The firm is undervalued and projects very high probability of distress for the next 2 years. Our latest 90 days buy vs. sell advice on the firm is Strong Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Assertio Holdings. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com